AstraZeneca (NYSE: AZN) reported updated clinical outcomes across its oncology portfolio, highlighting sustained long-term survival advantages for its lung cancer treatments.

The company’s adjuvant drug TAGRISSO (osimertinib) demonstrated a sustained overall survival benefit at eight years in the ADAURA Phase III trial for early-stage EGFR-mutated non-small cell lung cancer. The updated exploratory results, presented at the IASLC 2026 World Conference on Lung Cancer in Seoul and published in the Journal of Thoracic Oncology, showed TAGRISSO reduced the risk of death compared to placebo by 47% in the primary population (Stages II-IIIA). In the overall trial population (Stages IB-IIIA), the risk reduction was 48%.

Survival Outcomes

At eight years of follow-up, an estimated 74% of patients treated with TAGRISSO were alive in the primary population, compared to 58% of those on placebo. In the broader trial population, 79% of TAGRISSO-treated patients survived to eight years versus 64% on placebo.

Roy S. Herbst, MD, PhD, principal investigator in the ADAURA trial, noted a 16 percentage point improvement in overall survival at eight years with TAGRISSO versus placebo. He emphasized that this benefit persisted despite high rates of crossover to osimertinib following disease recurrence.

In advanced settings, FLAURA2 trial data reinforced benefits of combining Tagrisso with chemotherapy, displaying consistent long-term safety.

Advanced Lung Cancer and Breast Cancer Updates

Phase 3 DESTINY-Lung04 trial results presented by Daiichi Sankyo showed Enhertu reduced the risk of disease progression or death by 37% versus standard pembrolizumab plus chemotherapy as a first-line treatment for HER2-mutant non-small cell lung cancer. Enhertu achieved a median progression-free survival of 14.3 months compared to 8.3 months for standard care, alongside a 70.0% objective response rate. The objective response rate with Enhertu was 70.0% versus 44.5% with pembrolizumab plus chemotherapy. Median duration of response was 13.4 months for Enhertu and 9.7 months with standard care. Overall survival data were 46.9% mature, with no formal hypothesis testing performed due to imbalanced subsequent therapy patterns.

In breast cancer, top-line results from the SERENA-4 Phase 3 trial showed Etcamah paired with palbociclib did not meet its primary endpoint of progression-free survival in ER-positive, HER2-negative patients, despite numerical improvements. However, the U.S. Food and Drug Administration recently granted accelerated approval to Etcamah in combination with a CDK4/6 inhibitor for adult patients with HR-positive, HER2-negative metastatic breast cancer featuring an ESR1 mutation.

What the Numbers Show

The data reveal a consistent survival advantage across disease stages, with the hazard ratio remaining stable between the primary (HR 0.53) and overall (HR 0.52) populations. The absolute survival gap widened slightly in the broader cohort, where the difference between treatment arms reached 15 percentage points (79% vs 64%) compared to 16 percentage points in the primary group, indicating robust efficacy even when including earlier-stage IB patients who generally have better prognoses.

Treatment Persistence and Safety

Real-world evidence presented alongside the trial data indicated that early discontinuation of TAGRISSO before completing the three-year course more than doubled the risk of disease recurrence or death. Final safety data from ADAURA confirmed no new safety concerns, with tolerability consistent with the established profile.

Susan Galbraith, Executive Vice President of Oncology Haematology R&D at AstraZeneca, stated the results reinforce TAGRISSO as the adjuvant standard of care and backbone therapy across stages of EGFR-mutated lung cancer.

AstraZeneca shares were up 1.86% at $163.14 during premarket trading Monday.

AstraZeneca (NYSE: AZN) reported that its investigational drug tozorakimab significantly reduced moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations in two replicate Phase III trials.

The OBERON and TITANIA trials demonstrated a 29% reduction in exacerbations among former smokers in the OBERON study and a 34% reduction in the TITANIA study. In the overall population of current and former smokers, the reduction was 30% in OBERON and 29% in TITANIA compared with placebo, while patients remained on standard inhaled care.

Efficacy Across Patient Subgroups

The pooled analysis of both trials revealed consistent efficacy across different baseline blood eosinophil counts (BEC), a key biomarker for COPD inflammation.

Tozorakimab is the first biologic to show statistically significant efficacy in patients with low eosinophil counts (below 150 cells/uL), expanding the potential addressable patient population beyond those with high eosinophilic inflammation.

What the Numbers Show

The data indicates a dose-response relationship between baseline inflammation and treatment benefit. Patients with higher baseline BEC (≥300) experienced nearly double the relative reduction in exacerbations (43%) compared to those with lower counts (<150, 23%). However, the statistically significant result in the low-eosinophil group suggests the drug’s mechanism—targeting interleukin-33 (IL-33) signaling—addresses inflammatory pathways independent of traditional eosinophil-driven models.

Regulatory Status and Safety

The US Food and Drug Administration has accepted the Biologics License Application for tozorakimab under Priority Review. The Prescription Drug User Fee Act date is anticipated in the first quarter of 2027, following the use of a Priority Review voucher. The drug is also under regulatory review in the EU and China.

Safety profiles were favorable, with injection-site reactions being the only reported adverse drug reaction. Additionally, an integrated analysis presented at the European Respiratory Society Congress 2026 showed tozorakimab reduced mucus plug scores, an emerging outcome measure linked to worse COPD prognosis.

Sharon Barr, Executive Vice President of BioPharmaceuticals R&D at AstraZeneca, stated the results set a new standard for COPD treatment outcomes in a broad population.